SHR-1049
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 17, 2026
SHR-1049-101: A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=200 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1